NCT05043675招募中早期 1 期
Director of Nuclear Medicine Department
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Assessment of [18F]APN-1607 Uptake Patterns by Regional SUV Values
研究概览
简要总结
The overall objective of this study is to evaluate the overall pattern of [18F]APN-1607 uptake in subjects with AD dementia
详细描述
- To expand the safety and tolerability profile for the administration of [18F]APN-1607 and PET scanning.
- To assess regional patterns of [18F]APN-1607 uptake.
- To evaluate the relationship between regional measures of [18F]APN-1607 uptake and measurements of AD disease severity, such as National Institute on Aging and Alzheimer's Association (NIA-AA) diagnosis, Mini-mental Status Exam (MMSE) score, and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 45 to 80 years, inclusive.
- •Has a diagnosis of AD dementia according to NIA-AA criteria, including significant impairment of activities of daily living.
- •Has a CDR score ≥ 0.5 at screening.
- •Has a MMSE score ≤
- •Brain MRI supports the diagnosis of AD and there is no evidence of other nervous system diseases.
- •Medications taken for symptomatic treatment of AD must have been stable for 30 days prior to screening and through completion of the neuropsychological battery.
- •If necessary, the subject can be accompanied by nursing staff.
- •Written informed consent must be obtained before any assessment is performed.
- •Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year (ie, 12 consecutive months with no menses without an alternative medical cause) or, if they are of childbearing potential, must commit to use a barrier contraception method or to abstinence for the duration of the study and must have negative serum and urine pregnancy tests.
- •Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method (ie, condom), or to abstinence for the study duration.
- •Male subjects must not donate sperm for the study duration.
- •Willing and able to participate in all study procedures.
排除标准
- •Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease.
- •Implants, such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI.
- •Intolerance to MRI noise or hermetic phobia.
- •Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds local guidelines, eg, above an effective dose of 50 mSv.
- •Current or prior history (within the last 10 years) of alcohol or drug abuse.
- •Pregnant, lactating or breastfeeding.
- •Unsuitable veins for repeated venipuncture
- •Has received any investigational drug or device for any purpose within 30 days of screening (or 5 half-lives of the drug, whichever is longer).
- •Known hypersensitivity to [18F]APN-1607 or its excipients
- •Has received a non-vaccine investigational treatment for Aβ within the last 3 months.
- •Has received a non-vaccine investigational treatment for tau within the last 3 months.
- •Any situation that the presiding officer of this study believes may cause harm or potential harm to any link related to this test.
研究组 & 干预措施
[18F]APN-1607
Experimental
For the injection, subjects will receive a target dose of 0.1~0.15mCi/Kg [18F]APN-1607 as a bolus injection.
干预措施: [18F]APN-1607 (Drug)
结局指标
主要结局
Assessment of [18F]APN-1607 Uptake Patterns by Regional SUV Values
时间窗: 36 months
\[18F\]APN-1607 uptake patterns will be assessed in regions of interest (ROIs) which relevant to AD pathology. Standard uptake value (SUV) will be calculated for each ROI, and standardized uptake value ratios (SUVRs) will be calculated by normalizing SUV of ROIs to the SUV of relevant reference region.
次要结局
- Safety and Tolerability Profile Measured by Adverse Events (AEs)(36 months)
研究者
FengWang
Director of nuclear medicine department
Nanjing First Hospital, Nanjing Medical University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy SubjectsMild Cognitive Impairment Due to Alzheimer's DiseaseHealthy VolunteersAlzheimer's DiseaseNCT04141150APRINOIA Therapeutics, LLC130
已完成
3 期
[18F]APN-1607 PET in Subjects With AD Compared to HCMild Cognitive Impairment Due to Alzheimer's DiseaseHealthy VolunteersAlzheimer's DiseaseNCT05542953APRINOIA Therapeutics230
已完成
1 期
Evaluation of [18F]APN-1607 as a PET BiomarkerProgressive Supranuclear PalsyHealthy VolunteersNCT05005819Invicro12
已完成
1 期
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy SubjectsHealthy VolunteersNCT03142724Molecular NeuroImaging6
已完成
1 期
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy SubjectsHealthy VolunteersNCT03472313Invicro2